A prospective observational study for the impact of pemafibrate on cardio-ankle vascular index (CAVI)

A prospective observational study for the impact of pemafibrate on cardio-ankle vascular index (CAVI) - PEMA-CAVI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046474

Enrollment

100

Registered

2022-01-04

Start date

2022-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertriglyceridemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients with hypertriglyceridemia who scheduled to treat with pemafibrate 2) patients with type 2 diabetes or ischemic heart disease

Exclusion criteria

Exclusion criteria: Patients who are not considered to have sufficient ability to consent or refuse Minor patients

Design outcomes

Primary

Measure	Time frame
Changes in CAVI after 6 months treatment	—

Countries

Japan

Contacts

Public ContactAtsuhito Saiki

Toho University, Sakura Medical Center Center of Diabetes, Endocrinology and Metabolism

atsuhito156@sakura.med.toho-u.ac.jp043-462-8811

Outcome results